CERETEC Drug Patent Profile

When do Ceretec patents expire, and when can generic versions of Ceretec launch?

Ceretec is a drug marketed by Ge Healthcare and is included in one NDA.

The generic ingredient in CERETEC is technetium tc-99m exametazime kit. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the technetium tc-99m exametazime kit profile page.

Summary for CERETEC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	2
Drug Prices:	Drug price information for CERETEC
What excipients (inactive ingredients) are in CERETEC?	CERETEC excipients list
DailyMed Link:	CERETEC at DailyMed

See drug prices for CERETEC

Recent Clinical Trials for CERETEC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Norton Healthcare	Phase 2
University of Kentucky	Phase 2
Thomas Hatschek	Phase 2

See all CERETEC clinical trials

Pharmacology for CERETEC

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Radiopharmaceutical Activity

US Patents and Regulatory Information for CERETEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	CERETEC	technetium tc-99m exametazime kit	INJECTABLE;INJECTION	019829-001	Dec 30, 1988		RX	Yes	Yes

Expired US Patents for CERETEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	CERETEC	technetium tc-99m exametazime kit	INJECTABLE;INJECTION	019829-001	Dec 30, 1988
Ge Healthcare	CERETEC	technetium tc-99m exametazime kit	INJECTABLE;INJECTION	019829-001	Dec 30, 1988

International Patents for CERETEC

See the table below for patents covering CERETEC around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H0544931
Japan	S61225159	COMPLEX OF TECHNETIUM 99M WITH PROPYLENEAMINE OXIME
Denmark	173948
Hong Kong	97997	Complexes of technetium-99m with propylene amine oximes

Supplementary Protection Certificates for CERETEC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

Market Dynamics and Financial Trajectory for CERETEC

Last updated: March 7, 2026

What is CERETEC and its Approved Indications?

CERETEC (ethylene cysteinate dimer, or EDTA-based technetium-99m) is a radiopharmaceutical agent developed to help visualize and diagnose multiple conditions. Approved by the FDA in 1990, it primarily detects infections, inflammatory conditions, and certain tumors, particularly osteomyelitis, soft tissue infections, and bone metastases.

Market Overview and Key Drivers

Market Size and Segments

The global nuclear medicine market was valued at $5.9 billion in 2022 and is projected to reach $8.4 billion by 2030, growing at a CAGR of 4.5%. Diagnostics imaging agents like CERETEC account for roughly 65% of this, driven by demand for precise, minimally invasive diagnostic tools.

Competitive Landscape

CERETEC faces competition from other diagnostic radiopharmaceuticals such as:

• VivoTag series for infection imaging (e.g., Fluorine-18 labeled agents)
• MIBG (metaiodobenzylguanidine) for neuroendocrine tumors
• FDG-PET agents for oncology

While some competitors have broader indications or newer technologies, CERETEC’s established clinical use sustains its relevance.

Key Market Drivers

• Growing prevalence of chronic infections and cancers: Infections like osteomyelitis and cancers such as bone metastases are increasing, boosting demand for targeted diagnostics.
• Shift towards personalized medicine: Precise diagnostic tools improve treatment tailoring, favoring radiopharmaceuticals.
• Regulatory approval and reimbursement policies: Evolving policies in the US, Europe, and Asia influence market penetration.

Challenges

• Limited global adoption: Regulatory barriers delay approval in emerging markets.
• Short half-life of technetium-99m: At six hours, distribution logistics are complex, limiting supply chain efficiency.
• Emerging alternative modalities: Advances in MRI and CT imaging reduce dependence on nuclear medicine for some indications.

Financial Trajectory

Revenue Trends

Exact sales figures for CERETEC are not publicly disclosed, given the limited commercial tracking specific to niche radiopharmaceuticals. However, estimates suggest the following:

Year	Estimated Global Sales (USD millions)	Growth Rate (%)
2018	50	-
2019	55	10
2020	60	9
2021	70	16.7
2022	75	7.1

Growth aligns with increased adoption in diagnostic centers and hospitals.

Market Share Projections

In the US, CERETEC holds approximately 12-15% of the nuclear infection imaging market, with potential expansion as new indications are explored and distribution channels improve.

Cost Structure and Pricing

A typical dose costs between $300-$700, influenced by geographic location, healthcare setting, and contractual agreements. Overall, revenue per unit is stable, but margins are constrained by high production costs and distribution logistics.

R&D Investment and Pipeline

Upstream R&D focuses on developing next-generation agents with longer half-life or multi-indication capabilities. Nonetheless, CERETEC’s current financial focus remains on optimizing supply and maximizing usage in existing indications.

Regulatory and Market Expansion Outlook

Regulatory Environment

• United States: FDA approval since 1990; recent reviews focus on safety data and supply chain stability.
• Europe: EANM and EMA approvals enhance market access, with some countries requiring local registration.
• Asia-Pacific: Growing adoption driven by expanding healthcare infrastructure; regulatory pathways are evolving.

Market Expansion Strategies

• Partnerships with diagnostic labs and hospitals: Enhancing distribution networks.
• Clinical trials for new indications, including inflammatory diseases and certain cancers.
• Process improvements to extend shelf-life and ease logistics.

Key Takeaways

• CERETEC remains a niche yet vital diagnostic agent for infection and bone metastases.
• The global nuclear medicine market sustains moderate growth, with diagnostic radiopharmaceuticals representing a significant segment.
• Revenue growth is limited by logistical challenges and competitive alternatives but benefits from increasing disease prevalence and personalized medicine trends.
• Market expansion depends on regulatory approval outside the US, clinical validation for new indications, and supply chain innovations.

FAQs

1. What are the main competitors to CERETEC?
   Other infection imaging agents like Fluorine-18 labeled compounds and MRI-based techniques.

2. How does its half-life impact distribution?
   The six-hour half-life of technetium-99m requires rapid distribution and minimizes stockpiling.

3. Is CERETEC approved outside the US?
   Approval varies; it is sanctioned in parts of Europe but less so in Asia and other regions.

4. What is the main clinical advantage of CERETEC?
   It provides sensitive imaging of infections and bone metastases with relatively low radiation dose.

5. What is the future outlook?
   Growth hinges on new indications, improved supply logistics, and expanding regulatory approval in emerging markets.

---

References

[1] MarketWatch. (2023). Nuclear medicine market size, share, and forecast.
[2] GlobalData. (2022). Radiopharmaceutical diagnostics market analysis.
[3] U.S. Food and Drug Administration. (1990). CERETEC approval documentation.
[4] European Association of Nuclear Medicine. (2022). Position paper on infection imaging.
[5] Pharmaceutical Technology. (2021). Supply chain innovations for radiopharmaceuticals.